Aktienanalyse zu BioHarvest Sciences Inc (BHST)BHSTBioHarvest Sciences Inc

BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol. It operates in the Healthcare sector.

Bioharvest Sciences Inc (BHST) is currently not a strong buy due to its low RSI of 32.086, indicating oversold conditions, and a significant year-to-date change of -69.87%. However, the company has shown revenue growth of 8% year-over-year in Q1 2026, with a projected annual revenue guidance of $42 million to $48 million, suggesting potential for recovery. The main risk is the forward P/E of 153.846, indicating high valuation expectations despite ongoing losses.